Dan Topping
CIO at B.P. MARSH & PARTNERS PLC
Replay available
Annual Results for the year ended 31 January 2026 hosted by B.P. Marsh & Partners (LSE:BPM) on Investor Meet Company, held 2026-05-27.

On 6ix: 6ix.com/event/bp-marsh-and-partners-plc-bpm-annual-results-for-the-year-ended-31-january-2026
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning, and welcome to the B. P. MARSHAN PARTNERS PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I'd like to submit the following poll. And then I'll hand you over to Dan Topping, CEO. Good morning, sir. Good morning, everyone, and thank you for joining us. I'm Dan Topping, the CEO of B. P. Marsh, and I'm joined today by Francesca Chappell, our CFO. Today, we'll be taking you through the group's annual results for the full year ended 01/31/2026. It's been another strong year for B. P. Marsh, one that demonstrates both the quality of our portfolio and the steady compounding that comes from doing the same thing well for a very long time.
0:46 Turning to Slide two, just to remind everyone of who we are and how we operate. We're a specialist investor in small to medium financial services businesses, predominantly insurance brokers and managing general agencies, at a scale in terms of start up or early stages where alternative funding is difficult to obtain. We've invested in 70 companies since inception with 24 active investments in the portfolio and we've been listed on AIM since 2006. Our edge is what we call bridging the gap. We invest at the enterprise value stage that sits between venture capital and mid market private equity. Typically, that means initial investments of up to 5,000,000 for 20% to 40% minority stakes in businesses with an enterprise value of between 0 and 25,000,000 at entry. Again, the focus is predominantly at the zero and as opposed to the 25,000,000 end.
1:40 Our team brings decades of sector knowledge and our average holding period is about six point four years, which reflects a long term patient approach that we think is generally different genuinely differentiated. What all of that is intended to produce ultimately is consistent growth in value over time and that brings us neatly to net asset value performance, which is encapsulated in slide three. This slide tells the story of what patients looks like in practice. Our NAV has grown from 40,600,000 in 2007 to 360,200,000 as at the 01/31/2026. That's an 11% compound annual growth rate over nearly twenty years. Not every year has been perfectly smooth, but the trajectory is remarkably consistent.
2:27 It really reflects the value of our model, minority stakes in growing businesses supported by patient capital and a partnership approach. These headline numbers are supported by another year of strong underlying financial performance. So I'll now hand over to Fran to take you through the detail of that financial performance. Thank you, Dan. I am pleased to present the annual results for the year ended 01/31/2026, with the group having had another strong year. NAV increased by GBP 33,800,000 or 10.3% in the year and is now GBP 360,200,000. This is equivalent to GBP 10.9 per share or GBP 9.60 per share diluted. The growth in NAV is driven by the rise in investment valuations and realized gains on disposals, whilst accounting for dividends and share buybacks that have taken place throughout the year.
3:21 Our equity portfolio is now valued at GBP 273,800,000 and increased by GBP 48,200,000 or 21.4% in the year after adjusting for realizations and additions. Dan will be covering the portfolio later in the presentation. Throughout the year, we completed eight new investments and made two realizations. Total dividends of GBP 8,000,000 were paid throughout the year, which then added to the growth in NAV resulted in a total shareholder return of 12.8. Profit for the year was GBP 49,000,000. Available capital at the year end stood at GBP 49,500,000, providing the group with a strong platform for continued new investment activity.
4:07 Slide five provides a breakdown of our NAV of GBP 360,200,000 and portfolio composition as of the 01/31/2026. At the year end, our investment portfolio was valued at GBP 2 and 73,800,000, whilst cash and other assets amounted to GBP 86,400,000. Post year end, the group has made two new investments into Nine Edge Wealth and Ventura Risk Partners. In addition to this, the group disposed of its investment in Omega Specialty. Slide six reports the breakdown of our cash and other assets. On the left of the slide, you will find a breakdown of our loan book as at the 01/31/2026, which stood at GBP38.8 million. This is an increase of GBP 13,200,000 on our loan book as at January 2025, reflecting the active deployment of loan capital during the year.
5:01 The average interest rate received on our loan book during the year was 8.8%. Details of our individual loans can be found on Slide 29 of the appendices. Post year end, the loan book has grown further and now stands at GBP 51,900,000 as of the May 26. On the right of the slide you will see that at the end of the year we held £49,500,000 in cash and treasury funds, down from £74,100,000 in January 2025. The decrease in cash reflects the significant capital deployed into new and follow on investments during the year, dividends paid and funds utilized for share buybacks. The group keeps its cash held with well known institutions in a mixture of short term and instant access deposit accounts, with a maximum deposit period of one month maintained throughout the year.
5:54 The average return on treasury funds for the year was 3.3%. Slide seven presents our dividend distribution history and our intentions looking ahead. During the year ended the 01/31/2026, the group paid total dividends of £8,000,000 equating to 21.64p per share. Looking ahead, by the end of our financial year ending January 2027, the company expects to have distributed a further £13,000,000 in dividends, which will bring the total dividends paid since flotation to £37,700,000 equivalent to 107.1p per share. To put that in context, the original flotation price was 140p per share, so we will have returned 76.5% of the flotation price to shareholders through dividends alone.
6:47 The Board intends to pay further dividends of £7,000,000 in our financial year ending January 2028. This slide also illustrates the clear link between portfolio realizations and dividends. Each of the major disposals in our history from Howden in 2013 to most recently SSLU in 2025 has contributed to our ability to make progressive dividends to shareholders. Slide eight presents our total shareholder return and share price performance. For the year ended 01/31/2026, the total shareholder return was 12.8%, comprising NAV growth and dividends paid during the year. Turning to the chart on the right of the slide, this shows the performance of the company's share price and NAV per share against the AIM AllShare and AIM Financial indices, rebased to 01/20/2010.
7:43 This long term outperformance reflects the strength and consistency of our investment model. I will now hand back to Dan to take you through the portfolio in more detail. Thanks, Fran. I'll pick things back up with a closer look at the portfolio itself, starting with an area that has been a long term strength for the group managing general agencies or as we call them MGAs, Slide nine. Our 11 MGA investments are collectively valued at £72,600,000 built on a total cost of £16,800,000 a 4.3 times multiple on invested capital. These businesses are expected to underwrite aggregate gross written premium of over £850,000,000 in 2026, producing over £90,000,000 in commission income. The portfolio spans markets in Australia, The UK, The U. S. And Europe and ranges from more mature companies like ATC, our largest individual MGA holding at £37,700,000 to more recent entrants in the portfolio like Cameron and Volt.
8:42 ATC has delivered an IRR of 36.2% over its holding period and we'll discuss that later in the presentation. Fiduciary, our longest standing MGA has delivered 32.4 times the invested capital and Volt, a more recent investment at a nominal cost of GBP 26 is already valued at GBP 4,250,000. MGA is an area we know well and where our network and sector expertise gives us a genuine origination advantage. We like the model, specialist underwriting expertise, scalable companies, strong cash generation and a market environment where access to insurer capital remains tight. Turning to Slide 10, our broking investments. Total value across the six broking investments is £182,000,000 built on a cost of £59,200,000 a 2.1 times multiple overall.
9:31 Collectively, our broking investments are budgeting to place more than £1,500,000,000 of gross written premium in 2026, generating over £140,000,000 of brokerage income. Pantheon remains the standout valued at £107,000,000 against a cost of £27,300,000 as at 01/31/2026, with an IRR of 150.4%. XPT, our U. Wholesale platform is valued at £64,000,000 with an IRR of 26.6% since our investment in 2017. More recently, we've backed One Global, a London headquartered international broker with 15 offices around the world offering products over a number of business areas. And SRT, our UK focused broking and asset finance company, or broker also continues to build momentum.
10:21 Turning to Slide eleven, alongside insurance, we selectively invest in adjacent UK financial services, businesses where our expertise, network and patient capital can support distinctive opportunities. IO finance is our buy and build platform in the alternative finance space, bringing together specialist SME lenders to address the funding gap left by high street banks retreating from SME lending. We invested £10,000,000 for an 8% stake in April 2025 alongside Janice Henderson as a co investor. Whilst at recent investment, we've got good hopes for this business and it continues to deliver momentum and is assessing further acquisition opportunities. Nine Edge Wealth was an investment post year end is a newly established independent financial advisory business founded by Derek Miles. He was a previous partner of B. P. Marsh. He grew Aspera, a previous B. P. Marsh investment to over £4,000,000,000 of assets under advice and its ultimate sale to Titan.
11:23 Nine Edge Wealth is an acquisition led IFA consolidator, tech enabled and already building scales having made two acquisitions since our investment. One theme you'll see increasingly across the portfolio is that where we back strong management teams, opportunities often emerge beyond the original investment thesis. Moving on to Slide 12, which is the overview of the XPT related insurance vehicles. There is also in the portfolio two purpose built vehicles linked to XPT's strategic growth, Gambit Re and XPT ProducerCo. Gambit Re is a collateralized reinsurance vehicle based out of Bermuda, providing risk capital to selected underwriting programs within XPT's underwriting arm, platinum specialty underwriters.
12:08 Again, an early startup investment for us. We've provided up to 5,000,000 of risk capital into this management up to $15,000,000 and an external private equity investor north of 75,000,000 to allow XBT's underwriting platform access to further capital, which we think further differentiates XPT and allows us to see meaningful returns from their underwriting portfolio. XPT ProducerCo is a platform that we created to recruit and incubate experience on insurance producers, solving a structural growth challenge within XPT that allows us to provide capital in an efficient way for them to grow. Both were established with BPMARSH backing in 2025 and illustrate very well how we can support our existing investments beyond the initial equity position.
13:01 Of course, while much of today's presentation focus on portfolio growth, it's equally important to show how that value is ultimately realized, which takes into Slide 13, realizations over the past five years. Over the past five years, BPMash has realized eight investments, generating total proceeds of £178,900,000 against an aggregate investment of just over £20,600,000 a money multiple of 8.7 times. Those realizations span underwriting agencies in Canada and Australia and The UK, as well as a UK broker and insurance intermediary group. IRRs across the cohort range from 8.8 to 111.9%. This track record of realization matters, it demonstrates that the NAV isn't just a number on a page or in a black box created by us, it shows how we convert these investments into real cash, which moves on to disposals during the year, Stuart Specialty Risk Underwriting SSRU, which demonstrates our model in terms of the smallest investments produce the most extraordinary outcomes.
14:06 The most significant disposal in the financial year was our exit from SSRU in December 2025, when the business was acquired by Ryan Specialty LLC, a US based insurance distribution platform. We invested in January 2017, backing its founder Stephen Stewart with a nominal equity investment of just approaching £19 There was a loan of about 500,000. But that was repaid within the first eighteen to twenty four months. So over the eight years of our investment, SSRU grew to become one of Canada's leading independent underwriting agencies, writing around CAD100 million of gross written premium and delivering strong EBITDA growth through that hold. We received total proceeds when we exited of £28,300,000 an IRR of 89.9% and given the original investment was £19 a realized profit figure that is for practical purposes almost identical to the sale proceeds.
15:03 It's It's one of those investments that demonstrates the full power of our model, find exceptional management, back them with long term capital, support them without interference and exit at the right moment. The second dispose in the year was Sterling Insurance in May 2025, a cross portfolio transaction that neatly illustrates our network's value. Sterling was a rather different type of success story, less dramatic perhaps, but strategically very valuable. We invested £1,900,000 in Sterling in June 2013 for just under 20%. And over twelve years, sterling strengthened its core construction liability lines and grew gross written premium from just under £40,000,000 to just approaching AUD55 million of premium exit. The exit was structured as a combination with ATC Insurance Solutions and other of our portfolio companies, with the transaction valued at £33,200,000 funded through cash and ATC equity, including a management rollover.
16:00 Proceeds to BPMash were £3,100,000 which we received via ATC shares, a 63% uplift on our position. And crucially for us, the combination the combined platform is stronger for it, which benefits us to an enlarged stake in ATC. While we realize value from mature investments, we're equally active redeploying capital back into new opportunities. Section to Slide 16, new investments in the year and post year end. Across the financial year, we made eight new investments totaling £27,800,000 of equity alongside two post year end investments in Nine Edge Wealth and Ventura Risk Partners. The breadth and pace of new investment activity reflects both the strength of our deal flow and the depth of our available capital, which I suppose neatly links us into Slide 17, new investments.
16:55 We're often asked where our deal flow comes from and the short answer without trying to be overly simplistic is relationships. We evaluated 61 new investment opportunities during the year broadly in line with the prior 62% came through referrals or introduction for our existing network and of those 43% were international in nature. By sector, 75% were in insurance distribution and 25% were general financial services. The message is that our deal flow is really genuinely proprietary. We don't rely on auction processes or intermediaries to find opportunities. Because of our model and our unique investment approach, we've created a position where we feel we're the preferred partner for entrepreneurial teams looking to maintain control, but access to financial institutional capital with a track record of delivering returns.
17:47 Moving on from new investments to Slide 18, which details deferred consideration over there. One feature of our model that can sometimes be overlooked is the long tail of our value creation after an initial disposal. Two legacy investments continue to generate cash through deferred consideration mechanisms. On LEBC, which we sold to Titan Wealth, equity proceeds to date are 5,700,000 with an IRR of 6.5% on a GBP £13,500,000 investment. Clearly, there were challenges with our investment in LEBC, but the way we were able to work with Derek Miles to take the business forward to exit and structure the exit with Titan meant that we received proceeds on exit, and then deferred consideration unattaching to performance criteria that, you know, improves our return materially post sale.
18:37 The first tranche of deferred consideration received in September 2025, meaningful amount, the second will follow over the course of this month and the third and final payment in 2027. We therefore expect to receive significantly more than our amount invested and we feel it was a positive outcome to an investment that was or without its challenges, but ultimately was a positive return to the company. On CBC UKPaladin, we sold this to Specialist Risk Group in March 2024. The story is now substantially complete. We received all deferred consideration due, totaling £18,700,000 giving us total proceeds of £62,700,000 and an IRR of 48.7%. To our mind, a remarkable outcome given the initial equity stake was GBP 3,005 Together, these examples reinforce an important point. Our realizations don't end at completion.
19:33 Often, we're able to come up with deferred structures, which continue to deliver return and value to BPMash quietly but meaningfully materially. Turning now to some of the individual portfolio highlights, it's difficult not to start with Pantheon. Slide 19. Pantheon remains our largest single holding and the most striking example of what early stage backing in the right management team can achieve. Founded in 2023, Pantheon now has over 45 employees, operating across six product lines and generating £24,800,000 of revenue and £18,000,000 of adjusted EBITDA in 2025. As at the year end, we held a 39% holding in Pantheon for a cost of GBP 27,300,000, which we valued at 107,000,000.
20:21 Post year end, we acquired a further 2% in Pantheon with our shareholding now being 41%. Pantheon began its life in global casualty as its specialism, but it's now moved into professional lines, property, innovation and technology, delegated authority, insurance premium has also just added marine. We can continue to expect to develop into other adjacent lines of insurance brokerage. It's got a strong track record now. It's very profitable. It's got a unique capital base within the market and we see it becoming more and more appealing to individuals or teams that like the ethos of the management team and like the nature of the private equity investment in terms of it is a long term play without any exit pressures because of the nature of how BPMARSH is structured to make investments.
21:15 The trajectory from 0 to 107,000,000 of value in under three years is obviously exceptional. And the financial year 2026 budget continues to project strong growth. It's the investment that frankly, we'd all hope to find once a decade and we're delighted to have found it in this one. I think, you know, we've talked about SSIU previously with Pantheon and I think this, you know, really illustrates BPMARSH's niche in terms of what we're able to do deploying our level of capital, which provides the opportunity for outsized returns. Where Pantheon represents rapid early stage growth, XBT reflects long term platform compounding at scale. Moving to Slide 20, XBT slide. XBT is our major U. S. Platform, a specialty lines insurance distribution group that's built a wholesale broking and underwriting agency across The U. S. Specialty sector.
22:08 We first invested in June 2017 and today we hold a 30.5% stake valued at £64,000,000 against the cost of £20,200,000 equity and just under £9,000,000 in loan funding. IRR to date is just over 26%. XPT now manages over US1 billion dollars of gross written premium, employs more than four fifty people across over 30 US offices and has completed 19 acquisitions since formation. And GWP has grown a compound annual growth rate of about 45%. And that shows where it is now. Back in 2017, it was three very credible individuals with a business plan that we were able to test support.
22:53 And again, it evidences our ability to find the right management team and grow it. They focus on the production and we focus on the working with them on the systems and controls, cash flow management and governance to provide the right support structure for very fast growing businesses. 2025 adjusted EBITDA was just under $25,000,000 and the full year '26 budget projects continued growth across revenue and profitability. And again, as sort of detailed earlier, this has been supported by new initiatives, including Gambit Re and XPT ProducerCo. Moving to Australia on Slide 21. ATC is now Australia's largest independent Lloyd's cover holder and a long standing core holding for us.
23:39 We first invested in July 2018 for about 20% and we now hold 27% valued at 37,700,000 against a combined cost of just over 5,000,000 once we factor in the investment in ATC, the rollover of MB Prestige and Sterling and IRR currently stands at just over 36%. ATC rights over AUD 200,000,000 of GWP, which delivered a 20% CAGR since our investments and 2025 EBITDA was just a tad north of 17,300,000. Its key product line span construction, accident and health, sports and leisure, cyber and other specialty lines, which we feel is a very well diversified book. ATC has completed three acquisitions during our hold and including the absorption of Sterling Insurance this year. The recent addition of Frontier Global, which actually wasn't a BPMark portfolio company, so shows how ATC is developing further expands ATC's reach into financial lines and London market distribution with Frontier having a London underwriting operation.
24:45 While still remaining consistent with the disciplined acquisition strategy we've seen from management over a number of years. So I think, you know, ATC has reached a scale that it can deploy capital with our support or with bank debt to continue to deliver this sort of outsized growth trajectory. And it's a business that's grown consistently, maintained underwriting discipline and expanded its reach and we expect that to continue. Moving away from the portfolio on Slide 22. Alongside portfolio growth, we remain very focused on the question of capital allocation, specifically balancing reinvestment with meaningful shareholder returns. Over the year, we paid £8,000,000 in dividends. And for the year ending 01/31/2027, we will pay total dividends of 13,000,000 GBP 10,500,000 of which was already paid and a further GBP 2,500,000 would be paid in July.
25:35 Lastly, shareholders can expect, subject to final Board approval, a minimum of GBP 7,000,000 for the year ending 01/31/2028. This would see dividends of totaling £44,700,000 having been distributed to shareholders by the year ending by our January 2028 year end. On share buybacks during the year, we repurchased just over 1,000,000 shares for £6,900,000 at an average price of $6.59 pence under the program we launched in April 2025. For the year, shareholder return stand at just under 13% and we think that's a fair reflection of a year of genuine progress. We think the balance between growth and liquidity and shareholder returns remains one of the defining strengths of the group.
26:23 Moving away from that on to Slide 23. Given what's being discussed, before we conclude, I think it's worth touching briefly on a topic that inevitably comes up in almost every investor conversation at the moment, artificial intelligence. For what it's worth, our view is that AI acts as an enabler, not a disruptor in the sectors that where we focus. We tend to be skeptical at the moment of grand claims where we are in this area, but practical workflow improvements are already becoming very real. The insurance and finance advisory industries will continue to need skilled brokers, underwriters and advisers. Why AI changes is we believe the workflow behind them, automating administrative bottlenecks, accelerating data processing and freeing professionals to focus on the work that requires judgment and relationships.
27:12 Three of our portfolio companies XPT, Nine Edge Wealth and Vault have built or are building their own AI tools that augment their teams in meaningful ways. Critically, all three maintain a clear principle, Humans check and verify every output. AI is applied selectively to tasks that previously demanded larger teams or extensive manual work. We'll be watching how this theme evolves across the wider portfolio and we'd rather be invested in businesses that are deploying AI thoughtfully than those ignoring it entirely. So to close, it's been a strong year, not defined by a single exceptional event, but by consistent progress across the portfolio and disciplined deployment of capital. Net asset value of 3 and 60,200,000, total shareholder return of 12.8%, portfolio value up 21.4%, eight new investments, two realizations, pounds 8,000,000 in dividends and over £30,000,000 of available capital to continue.
28:14 Strategically, our priorities remain unchanged, identifying back strong management teams and specialist markets, compound value over the long term and maintain a disciplined balance between investment, liquidity and shareholder returns. The company has now been doing this for over thirty years. The principles haven't changed and if anything, the opportunity set continues to grow. Thank you very much for your time and we'll now be very happy to take questions. Thank you for updating investors today. Could I please remind investors to submit your questions just by using the Q and A tab situated on the right hand corner of your screen? For your reference, a recording of today's presentation will be available on the Investor Me Company platform shortly after the meeting has ended. As you can see, we received a number of questions during today's presentation. Katie, if I could just hand back to you to read out the questions and give responses where appropriate to do so, and I'll pick up from you at the end. Thanks, Charlie. Thanks, Dan.
29:06 To begin with, there's been a question around the insurance market. And as parts of the insurance market are beginning to soften, how insulated is BPMarch's portfolio given the focus on specialty risk classes? Thanks, Katie. I think broadly speaking, I mean, insurance is a relatively defensive area as a generalization when risks start moving in and out of it and prices start hardening or softening as an overarching comment. But I would say the market is tending to soften as a general observation. That's, you know, a fundamental result of hardening prices for about twenty four to thirty six months, and it will continue. Suspect that being said and specific to the question, because we focus on startups or very early stage investments, it's and we're long term holders, it's we're somewhat even further insulated from that because clearly if you're a startup, if a premium was, for example, a £100 the year before you started and it was reduced to £80 the next year, it's still new business. So we we look at it from portfolio, not portfolio, actual accounts one versus the aggregate premium being placed because as long as that's growing, we see our portfolio companies growing.
30:30 Thank you, Dan. There's been a couple of questions around the discount to NAV. I'll just try and read a few out. So with the 30% discount of NAV, why wasn't a more aggressive share buyback implemented? And would you be open to selling the assets and return cash to shareholders if the discount doesn't reduce? And then carrying on a little bit more, someone's asked it would be useful to hear something about how the valuation of the of top three investments arrived at and that buybacks have been released reasonably small seemed reasonably small to date? And have they can management considered significantly increasing the scale of the buybacks helped to address the share price discount? I think dealing with the discount, clearly, that's something that we've we've focused on over over a long term period and I think you can see the long term trend is clear.
31:26 It's it's a key focus of the management team that that reduce the discount. I think I think there's always a theoretical market applied discount against our NAV because of the fact that we hold privately private company liquid holdings. But that being said, my view for what it's worth is the discount should be probably between 15 to 5% and it it has fluctuated at that. There was a material disposal by Ardona last year at a price that they were prepared to do that that caused the the nav to widen. It's it's starting to reduce, I think that's the focus of the the management team to to continue reducing that discount. I mean, on the sell all the assets and return share cash to shareholders, I mean, that's not the strategy of B.
32:21 P. Marsh. Certainly, over the last five to ten years as a meaningful shareholder from a personal standpoint in BPMARSH, I'm happy with the direction of travel in terms of the share price performance and the dividend yield. And I think so long as we can continue that share price performance trajectory and and when appropriate, maintain a good dividend yield. I think as a shareholder myself that that presents better long term returns for the shareholders and all stakeholders as opposed to a more short term approach of realizing the assets immediately to return cash to shareholders. Think that in some respects that could exacerbate the discount in NAV. In terms of the top three, and I think there's another point about concentration risk, which I'll sort of touch on first and then come back to the top three. Think actually, if you look at the portfolio from where it was ten or fifteen years ago of nine to 10 portfolio investments, a bit longer than that, when we had Hyperion.
33:19 At one stage, I think Hyperion equated to almost 60, if not more than 60% of the NAV. We were comfortable with that then. Ultimately, we realized Hyperion is a very successful investment, redeployed the proceeds and you can see from that sale and redeployment of the proceeds we kicked on and the company kicked on and did very well. So concentration risk in performing assets isn't something that we're concerned by, but it's something that we monitor, especially in line with their performance and look forward projections, which I hope sort of deals with that concentration risk question. I think we've got three big ones, but that's a they're almost a victim of their own success. Pantheon's a a very recent investment that's growing tremendously well. So I would hope rather than expect, I would hope we'd have more pantheons in the portfolio. And I think with the more recent, start up investments that that you can see they're starting to to grow significantly, and I I would imagine that the directional travel of that would be similar such that we'll have 24 portfolio companies all with a meaningful growth horizons.
34:27 On valuation methodologies, we've never released methodologies. We don't plan to start. I appreciate you can say that it it it leads to visibility being reduced on how we arrive at these valuations, but I've made the counterpoint over the last five years, we've got a very decent track record of realizing at or above our valuation. There is greater visibility on market comparison transactions, which people can benchmark us against if they want, and I'd say that demonstrates our conservative approach to valuations. But also a sort of wider commercial point is that often if we release the methodology when it comes to a disposal, it can be used against us in that kind of transactional nature on a sale, and we'd rather not have, our valuation methodology in the public and then used against us to the detriment of our underlying returns.
35:21 Thanks very much, Dan. And yeah, thanks for covering those concentration risk questions. Moving on, there's been a question whether independent brokers are becoming stronger or weaker competitively. Well, no. My confirmation bias on this insofar as obviously I think they're becoming stronger. I think it's cyclical. I think with where the market is in terms of consolidation, we've seen over a decade of brokers being consolidated into wider financial conglomerates. I think it's been successful for the consolidators, but it has led to people being disenfranchised by the consolidation and that that is a ready supply of new business opportunities. It's certainly as at today and what I think going forward to the future for the next twelve to thirty six months, I think we'll see a steady stream of, new start brokers approaching us. And if we get the right terms and the right business plan, I think we'll continue to support them.
36:20 I think, the way brokers are established from a capital standpoint remains capital light, which appeals to us. But also with technological advances and AI and all that stuff, it allows the smaller brokers to punch above their weight with access to data and management to data when it comes to winning clients. So I I say from the beginning that there is a level of unbiased from my opinion, but I think they're very well positioned for for new start brokers at smaller end. And there's a ready supplier of acquirers when they grow up to to scale. So if you look at Lily Plumber Risk, was in the portfolio, that was a a team of disenfranchised brokers that had got tired of being bought and sold. They established we provided them with the working capital at governance, oversight, and focusing on the dull stuff like financial reporting and cash flow.
37:15 And within five years, which is inside of our sort of preferred hold period, we were able to realize then a significant profit to a Goldman Sachs backed consolidator, and that still remains the optionality for us with the portfolio because there's a ready supply of investments at the bigger end looking to get into insurance distribution. Thank you, Dan. Another question a bit more generally on how active is the pipeline for new investments today? Yeah. I think, it's a continuation where we're seeing a good inflow of new business. I think it's all well and good having an active pipeline, but not that great if you can't do the deal. So we could have a thousand inquiries and not do one transaction where our approach over the years is to sort of refine the process to sort of sort the week from the chaff in terms of what our investment appetite.
38:14 I think we've been successful at that. And so I think we've got a very good pipeline of transactions that we'd like to pursue subject to getting the right terms for BPMorgan shareholders. So I think we'll continue to see a good flow of doable new business deals. Thank you, Dan. There's been a question around what has caused Asian reinsurers drop in value. I think, you know, we've written it down by a £150,000 or so, so it's not materially impacting the overall NAV, but I suppose it speaks to our, you know, rigorous focus on valuations that we do care about, the smaller ones just as much as the big ones. And if the performance is adversely affected in the short term, we'll go after the valuation from a conservative standpoint, notwithstanding some people might consider it immaterial in the overall.
39:03 Looked at it, its performance was slightly down. We do have expectations that it will correct and in the long run be a good investment, but we actively monitor the portfolio and aggressively go after valuations if we think that there needs to be a reduction in terms of our conservative approach. Thank you. There's a question around the doubling of the new investments during the year compared to full year 2025. Do you see this new level as the norm or do you even expect to continue to increase this? I think probably somewhere in the middle. I would say we're unique in our offering. There is no one out there that structures transactions as long term investors with minority positions.
39:48 That's certainly becoming, to our mind, more popular, and we're seeing lots of people buying into that approach. Clearly, the proof of the pudding is that the the strength of the portfolio and the realizations, which again increases visibility. So I think we'll continue to be active. We've got a good pipeline, as I said earlier. So, yeah, I'd say somewhere in the middle. Thank you very much. Having a quick look at, balancing liquidity, investments, deployments and shareholder return, just a little bit more around, the balancing of that? Well, we think we balance it quite well in terms of we've got we flag dividends and we always try and give long term visibility on dividends germane to realizations, investment deployments. Obviously, we talked about new business and we continue to see an active new business pipeline. And liquidity on the balance sheet, we detailed in the presentation. Think, look, there is no hard and fast rule, but that's what we like. We like flexibility to try and deliver shareholder returns. It's what we expect from our portfolio companies. And I think, you know, it is a balancing act, but certainly, we feel we've struck the right balance so far.
41:11 Thank you very much, Dan. Looking ahead, where do you see the biggest opportunities and risks for the group over the next twelve to fourteen months? Slightly boring answer, but I think, the greatest opportunities are sticking to our knitting. I think we've created a niche for ourselves. We are a unique proposition and it continues to resonate within the market. So I sort of think, you know, whilst it's not revolutionary, I think what we present speaks for itself in terms of returns and that's where the opportunity remains. Certainly over the short to midterm, I wouldn't give long term projections. Risks, I mean, we're insurance focused as an investor. We have financial service mandate, it's predominantly insurance.
42:00 Insurance by its very nature is focused on risk. So, you know, there's the general macroeconomic issues that pop up that have popped up, and I won't dwell on them too much. But, you know, we've come through the global financial crisis at BPMarch, we've come through COVID, it's shown the resilience of the portfolio and the sector, and therefore, always be risks, you know, economic, societal. But I think as long as we proactively manage them and, you know, maintain our focus, and I suppose the opportunity by sticking to our knitting and what we've been successful at, and so long as there continues to be, you know, an active pipeline of new business, which there is, we manage the risk on that basis. Clearly, if I certainly if it appeared that our the furrow that we plow ceases to be doable, present active returns, then clearly, we would then say, we've done a we're very pleased with the job we've done, but we'll start realizing investments and returning to the portfolio because the unique proposition that we have isn't appealing anymore, but I don't see that in the short to medium term.
43:10 Great. Thank you so much, Dan. Just before we shortly conclude the presentation, it'd be great if you could just, recap on the presentation, provide any final comments. Yeah, hopefully, detailed, you know, how we performed over the year. Clearly, we're tremendously happy with what we've achieved and, you know, how the portfolio is set for the future. I think there's huge potential upside in there and we've got an active new business pipeline. So I think that's the summary in some in finalizing, you know, I've got to pass on them. Thanks to the team who've done the work and the portfolio have delivered the results to allow us to present these results. So I want to note that it's a huge team effort at BPMarch and the portfolio in delivering this. Thanks to the team.
43:59 Clearly, there's been, as of today, a few board changes at the PLC level with Brian Marsh that coming down off the board but remaining as president. And I just think it's worth noting, you know, the thanks of the team and myself personally for Brian for, you know, what he's you know, that BPMARSH is the house that Brian built over a thirty year period. He's he's then brought in a team around and him to support and take the business forward. I've worked with Brian for nearly two decades. He's been, you know, tremendous resource for me in building my contacts, building my experience and understanding the market we operate in. And what he's done is allowed the business to kick on in increments and I think, you know, as a team and as shareholders, Brian's created something, you know, that has been tremendously successful. And I just want to say, get it on record that we're thankful for that. But also, it's not goodbye to Brian.
44:58 He he still will remain in the business in an advisory capacity and ambassadorial role because he's a tremendous resource. Thank you, Dan, for your presentation this morning. You please ask investors not to close this session as you'll now be automatically redirected to provide your feedback, which will help the company better understand your views and expectations. On behalf of the management team of BPMARSH and PARTNERS PLC, we would like to thank you for attending today's presentation, and good
Follow B.P. Marsh & Partners PLC into a list and get an email when it puts out news.
CIO at B.P. MARSH & PARTNERS PLC
CFO at B.P. MARSH & PARTNERS PLC